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The GRAVITAS (Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety) study has demonstrated the detrimental impact of high on-treatment platelet reactivity following stent implantation and the failure of a double clopidogrel maintenance dose to reduce cardiovascular events in patients deemed clopidogrel non-responders ( Fig. 1 ) [1] . However, there was still evidence after the GRAVITAS study to support personalized medicine-based on platelet reactivity. The combination of a low-risk population together with platelet reactivity assessment after percutaneous coronary intervention (PCI) was recognized as a relevant limitation that may have accounted for the negative results of the GRAVITAS study.
The TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel) study design was similar to that of the GRAVITAS study, but treatment intervention was more aggressive, using prasugrel instead of an increased clopidogrel maintenance dose (Fig. 1) . The study was stopped prematurely due to a low event rate [2] .
Platelet reactivity has been consistently reported as an independent predictor of 'hard' post-PCI endpoints, including stent thrombosis, myocardial infarction and cardiovascular mortality (Fig. 2) [3, 4] . Notably, the hazard associated with high platelet reactivity is greater in patients with an acute coronary syndrome (ACS) than in patients undergoing PCI for stable angina; it accounts for approximately 60% of the definite/probable stent thrombosis events, demonstrating the dominant contribution that inadequate P2Y 12 receptor inhibition makes to thrombotic events [5, 6] . As a consequence, the bedside platelet function test has become an opportunity to guide antiplatelet therapy, particularly when there is an unexpected complication. This is also the case when new P2Y 12 inhibitors are not available, in the absence, however, of a recommendation for this type of use [7, 8] . The ARCTIC (Assessment with a double Randomization of [1] a fixed dose versus a monitoring-guided dose of aspirin and Clopidogrel after drug-eluting stent implantation and [2] Treatment Interruption versus Continuation, 1 year after stenting) multicentre randomized study sought to determine whether a strategy based on systematic platelet function testing to tailor antiplatelet therapy is superior to standard care in 2440 patients with stable angina or non-ST-segment elevation ACS (NSTE-ACS) undergoing PCI [9] . In contrast to the GRAVITAS trial, this study randomized the use of platelet function testing with treatment intervention (monitoring arm) versus standard of care according to clinician's preference without platelet function test (conventional arm) (Fig. 3 ). In the monitoring arm, serial platelet function tests (before stent implantation and during the maintenance phase) and treatment adjustments using a predefined treatment algorithm were performed. In addition to treatment intensification due to high on-treatment platelet reactivity, patients could be switched back from prasugrel to clopidogrel after PCI if low on-treatment platelet reactivity was measured. Despite halving the rate of high platelet reactivity to adenosine diphosphate (Fig. 4) , the primary endpoint of death, myocardial infarction, stent thrombosis, stroke or urgent revascularization was similar after 1 year with the two strategies (hazard ratio [HR] 1.13, 95% confidence interval [CI] 0.98-1.29; p = 0.10).
The take-home message is that platelet reactivity is not only a measure of drug response, but also integrates the effect of response to P2Y 12 receptor antagonists and comorbidities, such as advanced age, diabetes and renal insufficiency. Platelet reactivity should also be considered as a surrogate marker for studies on antiplatelet treatments that may be helpful to explain the results of trials. This has been confirmed by the prespecified pharmacodynamic TRILOGY-ACS (A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed) study, which demonstrated a real effect of treatment intensification but a lack of independent relationship between platelet reactivity and clinical outcome [10] . Such results further support the lack of benefit of intensification of antiplatelet therapy in medically managed patients [11] (Fig. 5) .
What is the future of platelet function testing? The level of recommendation for routine platelet function testing in patients who undergo stent placement will remain low in accordance with the negative results of recent randomized studies (Table 1) [1, 2, 9] . Platelet activity rather appears as a reliable risk stratification approach but not as a modifiable risk factor that may help to guide therapy. However, the ARCTIC study has evaluated neither the accuracy of platelet function testing specific to the treatment effect of P2Y 12 inhibitors, such as vasodilator-stimulated phosphoprotein (VASP), nor the combination of fast genotyping with platelet function testing in clopidogrel-treated patients. Fast genotyping is now available to identify clopidogrel metabolizer profile and guide P2Y 12 inhibition strategy, especially in ACS patients [12, 13] , with the possibility of having patients in a prespecified window of platelet inhibition to avoid both bleeding and ischaemic events. In the ARCTIC study, half of the patients were genotyped; whether there is a significant interaction between treatment monitoring and clopidogrel metabolizer profile may generate new research hypotheses.
Low platelet reactivity has been associated with major bleeding, a common complication of the more potent P2Y 12 inhibitors and a strong determinant of cardiovascular mortality. In the ARCTIC study, treatment monitoring was associated with a non-significant reduction in major Platelet function testing may be considered in selected cases when clopidogrel is used. Several trials currently under way may clarify the impact of adapting therapy on the basis of the results of platelet reactivity assays, but, so far, the routine clinical use of platelet function tests in clopidogrel-treated patients with ACS cannot be recommended and minor bleeding (3.1% versus 4.5%, HR: 0.69; 95% CI: 0.46-1.05; p = 0.08). We may therefore expect that bleeding in patients at low ischaemic risk may be the future of treatment monitoring. This is in line with a recent investigation of bleeding risk in patients undergoing coronary artery bypass graft (CABG) surgery. A strategy based on preoperative platelet function testing to determine the timing of CABG in clopidogrel-treated patients was associated with the same amount of bleeding observed in clopidogrelnaive patients and a waiting time that was approximately 50% shorter than that recommended in current guidelines [14] . These results led to an upgrade in the guidelines, to base timing of surgery on platelet function monitoring rather than the arbitrary use of a specified period of delay [15] .
Personalized antiplatelet therapy is looking at the patient with a different approach to the routine clinical approach. It is not a wrong approach per se. We are just at the beginning of the story and platelet function monitoring should be envisioned as an attractive approach to refining antiplatelet strategy in gravely ill and fragile patients. This is the specific objective of the ongoing ANTARCTIC (Assessment of a Normal versus Tailored dose of prasugrel After stenting in patients aged > 75 years to Reduce the Composite of bleeding, stent Thrombosis and Ischemic Complications; NCT01538446) trial, which is looking at the net clinical benefit of P2Y 12 inhibition in elderly ACS patients who undergo stent implantation (Fig. 6) . What we need is the right test in the right population with the right antiplatelet dosing regimen. 
